LucidQuest’s Post

Thoughts on this? >> Moderna partners with Blackstone on flu shots, nabbing up to $750M in R&D funding >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharma #pharmaceutical #healthcare

Thoughts on this? >> In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #biotech #pharmaceutical

Thoughts on this? >> In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly's support >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing

🎉Congratulations from Checkmate Equity🎉 💼Company: Attovia Therapeutics💰#Funding: $105Million⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. 🚀OFFLOAD YOUR CAP TABLE MANAGEMENT TASKS TODAY🎉 Checkmate Equity is a trusted Carta partner with experience managing over 2,000 #captables. Our expertise ensures compliance, accuracy, and timely updates for your cap table. With a dedicated Equity Administrator, we streamline the process, ensuring rapid updates. 🚀 Tao Fu and Zaneta Odrowaz, let me know if you need assistance with the adjustments to your Cap Table. 📊

Explore the latest PE/VC deals and transformative industry insights at www.vccircle.com! Stay competitive with VCCircle's expert analysis. Stay updated with insights from industries like: EvenUp | Haber | Accel India | BEENEXT | Spry Therapeutics | Flourish Ventures | Equirus | Amicus Capital #StayInformed #BusinessExcellence #PEVCDeals #InnovationJourney #EntrepreneurialSpirit #InsightfulNews #WeeklyUpdates #WeeklyDealsWrap #VCCircleInsights

Thoughts on this? >> Regeneron’s $500M fund spotlights corporate venture’s influential role in biotech >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #pharmaceutical #biotech

Ahead of BIO-Europe, our In Vivo journalists have explored some of the biggest deals and trends that have already shaped the start of 2024. Read on as we discuss what big pharma is looking for in strategic partners, who really were the biggest deal makers of 2023, what private equity and VC have been investing in, and why new company creation has slowed down. https://lnkd.in/g9xKcFWG

Thoughts on this? >> Alumis aims for this year’s third-largest biotech IPO as it readies for Phase 3 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #healthcare #biotech #pharma

Thoughts on this? >> Alumis aims for this year’s third-largest biotech IPO as it readies for Phase 3 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #productmarketing

venBio Closes $528 Million Life Sciences Fund V Learn more & get our take 👇 https://lnkd.in/ghUkQKsh “With a highly concentrated portfolio and active involvement in each company, we are proud to have helped build companies that have achieved nine FDA drug approvals over the past six years, with many more generating promising clinical efficacy and safety data.” — Dr. Aaron Royston, M.D., Managing Partner at venBio “Our portfolio is directly impacting patient lives, and we could not have achieved this without the ongoing commitment from our limited partners. Fund V is structured to enable us to continue our proven approach of being highly selective in company building, while doubling down on winners around key inflection points, including in crossover rounds and at IPO.” — Dr. Corey Goodman, Managing Partner at venBio “In structuring Fund V, our primary goal was to maintain consistency in our strategy, core team and investment discipline, and we look forward to her continued contributions to the firm.” — Dr. Richard Gaster, M.D., Ph.D., Managing Partner at venBio #funding #lifesciences #SoHCNews